

# Hepatoma-Specific AFP (H-S AFP) in the Diagnosis of Hepatocellular Carcinoma

Thesis

*Submitted for Fulfillment of the Master Degree in  
Tropical Medicine*

By

Nehal Rashad Mohammed

***MB. B.Ch***

***Faculty of Medicine– Cairo University***

Under Supervision of

Prof.Dr. Mohammed Serag Eldin Zakaria

***Professor of Tropical Medicine***

***Faculty of Medicine – Cairo University***

Dr. Iman Mohammed Hamza

***Assistant Professor of Tropical Medicine***

***Faculty of Medicine - Cairo University***

Dr. Dina Farook Elgayar

***Assistant Professor of Chemical and Clinical Pathology***

***Faculty of Medicine-Cairo University***

Faculty of Medicine

Cairo University

2011



*First and foremost, I thank God for helping and guiding me in accomplishing this work.*

*I would like to express my sincere gratitude to Prof. Dr. Mohammed Serag Eldin Zakaria, professor of Tropical Medicine, Faculty of Medicine, Cairo University, , for his great support, his active guidance and overwhelming kindness throughout this work.*

*A special tribute to Prof. Dr. Iman Mohammed Hamza, Assistant Professor of Tropical Medicine, Faculty of Medicine, Cairo University, for her sincere supervision, stimulating views and faithful advice.*

*I must extend my warmest gratitude to Prof. Dr. Dina Farook Elgayar Assistant professor of Chemical and Clinical pathology, Faculty of Medicine, Cairo University, for his great help and support to me.*

*Finally, no words can express my deepest appreciation and gratitude to my family for their never ending support and care.*

---

 *Nehal Rashad*



قَالُوا سُبْحَانَكَ لَا عِلْمَ لَنَا  
إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ  
الْعَلِيمُ الْحَكِيمُ

صدق الله العظيم  
سورة البقرة الآية (٣٢)

## Abstract

Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide and it is one of the major causes of death. HCC is now a rather common malignancy in Egypt which usually develops on top of liver cirrhosis secondary to viral infection. HCC diagnosis is a multistage process including clinical, laboratory, imaging and pathological examinations. The AFP diagnostic accuracy is unsatisfactory and questionable because of low sensitivity, therefore there is a strong demand by clinicians for new HCC-specific biomarkers. The lens culinaris agglutinin (LCA)-reactive alpha-fetoprotein (AFPL3) is percentage of total AFP concentration and it is the major glycoform in the serum of HCC patients

**Aim:** The aim of this study was to investigate the potential role of Hepatoma-Specific AFP (AFPL3) as a diagnostic non-invasive marker for HCC, in order to add a beneficial diagnostic value in patients with low levels of alpha-fetoprotein (AFP) and suspected to have HCC.

**Methods:** This study was conducted on **27** HCC patients with and **30** cirrhotic patients with no evidence of HCC; as well as **31** healthy subjects who served as control group.

We determined the level of AFP and AFPL3 for all cases together with full clinical assessment, liver biochemical profile, conventional ultrasound (US), abdominal triphasic CT scan.

**Results:** We found that there was positive correlation between AFPL3 and total AFP, also AFPL3 was significantly elevated in the HCC group comparing to cirrhosis and control groups. The higher total AFP the higher AFPL3 percentage. The diagnostic sensitivity of AFP at a cutoff 22.6 ng/ml was 83% and the specificity was 83%. The cutoff level of AFPL3 for diagnosis of HCC in this study was 5%, with a sensitivity and

specificity of 96% and 83% respectively. There was a significant elevation of AFPL3 with patient whose total AFP level (10-200) with increasing specificity and PPV to 100% at cut off 3.8%. There was no positive correlation between AFPL3 and the number or the size of hepatic focal lesions in HCC patients.

### **Conclusion:**

- AFP-L3 is a useful adjunct marker in the diagnosis of HCC
- In the grey zone patients where AFP determination is alone clueless in the diagnosis of HCC, the addition of AFP-L3 has a 100 % specificity and 100% PPV
- Outside the grey zone patients AFP may suffice in the diagnosis of HCC, where AFP-L3 is not detectable if total AFP is less than 10 ng/dl and if total AFP is more than 200 it would obviously trigger calling for another confirmatory modality.
- AFP-L3 offers no correlation to the clinical or ultrasonographic features of tumors

### **Key words:**

- Hepatocellular carcinoma (HCC).
- Alpha-fetoprotein (AFP).
- Hepatoma-Specific AFP (AFPL3).

# List of Contents

Subject	Page
List of Abbreviations	I
List of Tables	IV
List of Figures	VI
Introduction	1
Aim of the Work	5
Review of Literature:	
Chapter (1): Epidemiology of HCC	6
Chapter (2): Presentation and Natural History of HCC	27
Chapter (3): Laboratory and Radiological Diagnosis of HCC	41
Patients and Methods	84
Results	94
Discussion	120
Summary	133
Conclusion	136
Recommendations	137
References	138
Arabic Summary	1

## *List of Abbreviations*

<b>AASLD</b>	American Association for the Study of Liver Disease
<b>AFB1</b>	Aflatoxin B1
<b>AFP</b>	Alpha fetoprotein
<b>AFP mRNA</b>	Alpha fetoprotein mRNA
<b>AFPL3</b>	Alpha fetoprotein L3
<b>AJCC</b>	American Joint Committee on Cancer
<b>ALT</b>	Alanine transaminase
<b>AST</b>	Aspartate transaminase
<b>BCCLC</b>	Barcelona Clinic Liver Cancer
<b>CCDS</b>	Color code Duplex sonograph
<b>CEA</b>	Carcinoembryonic antigen
<b>CLDs</b>	Chronic liver disease
<b>CLIP</b>	Cancer of the Liver Italian Program
<b>CT</b>	Computerized tomography
<b>CTA</b>	Computerized tomography arteriography
<b>CTAP</b>	Computerized tomography arteriportography
<b>DCP</b>	Des- $\gamma$ -carboxy prothrombin
<b>ETs</b>	Endothelins
<b>FNA</b>	Fine needle aspiration

<b>GGT</b>	Gamma glutamyl transpeptidase
<b>GGT mRNA</b>	Gamma glutamyl transferase mRNA
<b>HBsAg</b>	Hepatitis B virus surface antigen
<b>HBV</b>	Hepatitis B virus
<b>HCC</b>	Hepatocellular carcinoma
<b>HCV</b>	Hepatitis C virus
<b>H-S AFP</b>	Hepatoma –Specific AFP
<b>IARc</b>	International Agency for research on cancer
<b>IGF-II</b>	Insulin-like growth factor $\beta$
<b>IL8</b>	Interleukin-8
<b>IOUS</b>	Intraoperative ultrasound
<b>LC</b>	Liver cirrhosis
<b>LCA</b>	Lens-culinaris agglutinins
<b>LCSGJ</b>	Liver cancer study group of Japan
<b>MAGE</b>	Melanoma antigen gen
<b>MRI</b>	Magnetic resonance imaging
<b>NAFLD</b>	Non-alcoholic fatty liver disease
<b>NASH</b>	Non-alcoholic steatohepatitis
<b>P53</b>	Protein 53
<b>PCR</b>	Polymerase chain reaction
<b>PCT</b>	Porphyria cutanea tarda



<b>PET</b>	Positron emission tomography
<b>PIVKA</b>	Prothrombin induced by vitamin K absence II
<b>PPV</b>	Positive predictive value
<b>RTPCR</b>	Reverse transcription PCR
<b>TGF-B1</b>	Transforming growth factor beta1
<b>TNM</b>	Tumor- nodes-metastasis
<b>TSH</b>	Thyroid stimulating hormone
<b>VIP</b>	Vasoactive intestinal peptide

## *List of Tables*

<b>Table No.</b>	<b>Title</b>	<b>Page</b>
<b>Table (1)</b>	Global frequency of new cases of hepatocellular carcinoma	9
<b>Table (2)</b>	HCC risk development factors	11
<b>Table (3)</b>	Paraneoplastic syndromes associated with HCC	34
<b>Table (4)</b>	Definition of the AJCC/UICC TNM Classification by the International Union against Cancer (UICC)	37
<b>Table (5)</b>	Definition of the LCSGJ TNM classification by the Liver Cancer Study Group of Japan and the JIS scoring system	38
<b>Table (6)</b>	Diseases associated with increased serum AFP concentration	43
<b>Table (7)</b>	Diagnostic values of AFP as HCC biomarker	46
<b>Table (8)</b>	EASL consensus diagnostic criteria for HCC	79
<b>Table (9)</b>	Diagnostic criteria for HCC	81
<b>Table (10)</b>	Modified Child score	86
<b>Table (11)</b>	Steiner-Edmondson grading system	90
<b>Table (12)</b>	Demographic features of the studied groups	95

<b>Table No.</b>	<b>Title</b>	<b>Page</b>
<b>Table (13)</b>	Comparison of clinical features of the studied Patients	97
<b>Table (14)</b>	Haematological tests of the studied groups	98
<b>Table (15)</b>	Liver biochemical profile of the studied patients	99
<b>Table (16)</b>	Child classes of the HCC and LC patients	101
<b>Table (17)</b>	Sonographic findings of the studied patients	102
<b>Table (18)</b>	Ultrasonographic characteristics of the focal hepatic lesions in HCC patients	104
<b>Table (19)</b>	Median levels of AFP and AFPL3 in studied groups	106
<b>Table (20)</b>	Comparison between Child classes and AFP, AFPL3 in studied patients	104
<b>Table (21)</b>	The sensitivity, specificity, positive predictive value and negative predictive values of total AFP and AFPL3 in HCC and cirrhotic patients	105
<b>Table (22)</b>	Categorizing the patients according to AFP level	110

<b>Table No.</b>	<b>Title</b>	<b>Page</b>
<b>Table (23)</b>	Comparison of AFPL3 level in relation to AFP levels	110
<b>Table (24)</b>	Shows sensitivity, specificity, positive predictive value and negative predictive values of AFPL3 in subgroup of patients with AFP level between 10ng/ml to 200ng/ml	112
<b>Table (25)</b>	Correlation between AFP level and other parameters in the studied patients	114
<b>Table (26)</b>	Correlation between AFPL3 level and other parameters in the studied patients	115
<b>Table (27)</b>	Correlation between AFPL3 with number & size of focal lesions in HCC patients	117
<b>Table (28)</b>	Summary of total AFP and AFPL3 values	119

## *List of Figures*

<b>Figure No.</b>	<b>Title</b>	<b>Page</b>
<b>Figure (1)</b>	The Barcelona Clinic liver cancer staging system	39
<b>Figure (2)</b>	The diagnostic strategy after detection of hepatic nodule by U/S	82
<b>Figure (3)</b>	Demographic features of the studied groups	95
<b>Figure (4)</b>	Demographic features of the studied groups	96
<b>Figure (5)</b>	Liver biochemical profile of the studied patients	99
<b>Figure (6)</b>	Child score among cases with HCC and liver cirrhosis	101
<b>Figure (7)</b>	Echogenicity among cases with HCC	104
<b>Figure (8)</b>	ROC curve for total AFP and AFPL3 (HCC versus cirrhosis).	108
<b>Figure (9)</b>	Comparison of AFPL3 values in relation to AFP values	111
<b>Figure (10)</b>	ROC curve for AFPL3 in relation to AFP level (10-200).	112
<b>Figure (11)</b>	Correlation between AFPL3 and AST in HCC patients	115
<b>Figure (12)</b>	Correlations between AFP and AFPL3 in HCC groups	118

## Introduction

Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world with a 5 year survival rate of less than 5% and an incidence of at least one million new patients per year (*Bruix et al., 2004*).

It is the most common primary malignant tumor of the liver (approximately 85-90%) (*El Serag & Rudolph, 2007*).

HCC incidence rate has been increasing over the last two decades of 20<sup>th</sup> century. In the United States, the reported incidence has increased to 4.7/100,000. The male population, both black and white, is primarily affected. However, the incidence of HCC in eastern Asia and middle Africa is more than five times that of North America. Furthermore, from 1981 to 1985 the peak incidence of HCC occurred in patients 80 to 84 years of age, whereas from 1991 to 1995 the peak was noted in persons 74 to 79 years of age. The shift in incidence toward younger persons seen over the last two decades coincides with the prevalence of hepatitis C virus infection (*Jorge and Marrero, 2003*).

Incidence of HCC in Egypt is currently increasing, which maybe the result of a shift in the relative importance of HBV and HCV as primary risk factors. HCC is the second most frequent cause of cancer incidence and mortality among men in

Egypt .Hospital based studies have reported an increase in Egypt (>95%asHCC), from 4.0% in 1993 to 7.3%in 2003 (*El-Zayaadi et al., 2005*).

Nowadays HCC diagnosis is a multistage process including clinical, laboratory, imaging and pathological examinations. The prognosis of HCC is mostly poor, because of detection at an advanced, non-resectable stage. Potentially curative treatment (surgery) is limited and really possible only for cases with small HCC malignancies. For this reason, more effective surveillance strategies should be used to screen for early occurrence of HCC targeted to the population at risk. So far, the generally accepted serological marker is  $\alpha$ -fetoprotein (AFP). Its diagnostic accuracy is unsatisfactory and questionable because of low sensitivity, therefore there is a strong demand by clinicians for new HCC-specific biomarkers (*Stefaniuk et al., 2010*).

Alpha fetoprotein (AFP) is a fetal specific glycoprotein produced primarily by the fetal liver. Normally, its serum concentration falls rapidly after birth and its synthesis in adult life is repressed. However, greater than 70% of HCC patients have a high serum concentration of AFP because of the tumor excretion. Forty years after its discovery, serum AFP remains a most useful tumor marker in screening HCC patients. The normal range for serum AFP levels is 10-20 ng/mL and a level